Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
4 "Woo-Chan Park"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Breast cancer
Marked Reduction in the Risk of Dementia in Patients with Breast Cancer: A Nationwide Population-Based Cohort Study
Jooyoung Oh, Hye Sun Lee, Soyoung Jeon, Jeong-Ho Seok, Tae-Kyung Yoo, Woo-Chan Park, Chang Ik Yoon
Cancer Res Treat. 2023;55(2):551-561.   Published online October 19, 2022
DOI: https://doi.org/10.4143/crt.2022.272
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
An inverse relationship between cancer and neurodegenerative disease, which presents the possibility of a reduced risk of dementia in cancer patients, has been suggested previously. However, a nationwide longitudinal population-based study of specific types of cancer with due consideration of treatment effects has not been conducted.
Materials and Methods
This nationwide population-based cohort study used data obtained in a 12-year period (January 2007- December 2018) in the Korean National Health Insurance claims database. All female breast cancer patients (age ≥ 50 years) diagnosed between 2009 and 2010 were included after excluding those with physician visits for any cancer during a 2-year period (2007-2008). Patients with senile cataract constituted the control group. The main study outcome was the risk of developing dementia.
Results
From a total of 90,396 and 85,906 patients with breast cancer and cataract, respectively, patients without behavior codes were excluded. Data for 15,407 breast cancer patients and 7,020 controls were analyzed before matching. After matching for comorbidities and age, either group comprised 2,252 patients. The median follow-up time was 104.1±24.0 months after matching. After matching, breast cancer was a predictor of a lower risk of for dementia (hazard ratio, 0.091; 95% confidence interval, 0.075 to 0.111; p < 0.001). In breast cancer patients, receiving chemotherapy and endocrine therapy did not significantly affect the incidence of dementia.
Conclusion
Breast cancer was associated with a remarkably decreased risk of dementia. The findings strongly suggest an inverse relationship between cancer and neurodegeneration, regardless of the adverse effects of cancer treatment on cognitive function.

Citations

Citations to this article as recorded by  
  • Timing of risk factors, prodromal features, and comorbidities of dementia from a large health claims case–control study
    Stefan Teipel, Manas Akmatov, Bernhard Michalowsky, Steffi Riedel-Heller, Jens Bohlken, Jakob Holstiege
    Alzheimer's Research & Therapy.2025;[Epub]     CrossRef
  • Bidirectional association between breast cancer and dementia: a systematic review and meta-analysis of observational studies
    Fuxing Bao, Liang Yu, Xiaolei Zhang, Qier Mu
    PeerJ.2025; 13: e18888.     CrossRef
  • Changes in the Emergency Department Visits Among the Older Adults With Dementia Before, and After the Nationwide Social Distancing Measures: An Interrupted Time Series Analysis
    Jeongmin Moon, Kyung‐Shin Lee, Ho Kyung Sung, Seonji Kim
    International Journal of Geriatric Psychiatry.2025;[Epub]     CrossRef
  • Association between Benzodiazepine and Dementia Risk in Treating Depression after Breast Cancer Diagnosis: A Nationwide Population-Based Cohort Study
    Taehwan Kim, Hye Sun Lee, Soyoung Jeon, Dooreh Kim, Eunjoo Kim, Woo-Chan Park, Chang Ik Yoon, Jooyoung Oh
    Yonsei Medical Journal.2025;[Epub]     CrossRef
  • Developing theragnostics for Alzheimer's disease: Insights from cancer treatment
    Hyun-ju Lee, Hee-Jeong Choi, Yoo Joo Jeong, Yoon-Hee Na, Jin Tae Hong, Ji Min Han, Hyang-Sook Hoe, Key-Hwan Lim
    International Journal of Biological Macromolecules.2024; 269: 131925.     CrossRef
  • 5,593 View
  • 175 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant
Hyung Seok Park, Jai Min Ryu, Ji Soo Park, Seock-Ah Im, So-Youn Jung, Eun-Kyu Kim, Woo-Chan Park, Jun Won Min, Jeeyeon Lee, Ji Young You, Jeong Eon Lee, Sung-Won Kim
Cancer Res Treat. 2020;52(3):680-688.   Published online January 28, 2020
DOI: https://doi.org/10.4143/crt.2019.351
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Recent studies revealed the BRCA1 c.5339T>C, p.Leu1780Pro variant (L1780P) is highly suggested as a likely pathogenic. The aim of this study was to evaluate clinicopathologic features of L1780P with breast cancer (BC) using multicenter data from Korea to reinforce the evidence as a pathogenic mutation and to compare L1780P and other BRCA1/2mutations using Korean Hereditary Breast Cancer (KOHBRA) study data.
Materials and Methods
The data of 54 BC patients with L1780P variant from 10 institutions were collected and the clinicopathologic characteristics of the patients were reviewed. The hereditary breast and/or ovarian cancer–related characteristics of the L1780P variant were compared to those of BC patients in the KOHBRA study.
Results
The median age of all patients was 38 years, and 75.9% of cases showed triple-negative breast cancer. Comparison of cases with L1780P to carriers from the KOHBRA study revealed that the L1780P patients group was more likely to have family history (FHx) of ovarian cancer (OC) (24.1% vs. 19.6% vs. 11.2%, p < 0.001 and p=0.001) and a personal history of OC (16.7% vs. 2.9% vs. 1.3%, p=0.003 and p=0.001) without significant difference in FHx of BC and bilateral BC. The cumulative risk of contralateral BC at 10 years after diagnosis was 31.9%, while the cumulative risk of OC at 50 years of age was 20.0%. Patients with L1780P showed similar features with BRCA1 carriers and showed higher penetrance of OC than patients with other BRCA1 mutations.
Conclusion
L1780P should be considered as a pathogenic mutation. Risk-reducing salpingo-oophorectomy is highly recommended for women with L1780P.

Citations

Citations to this article as recorded by  
  • Whole Exome-Wide Association Identifies Rare Variants in GALNT9 Associated with Middle Eastern Papillary Thyroid Carcinoma Risk
    Rong Bu, Abdul K. Siraj, Saud Azam, Kaleem Iqbal, Zeeshan Qadri, Maha Al-Rasheed, Saif S. Al-Sobhi, Fouad Al-Dayel, Khawla S. Al-Kuraya
    Cancers.2023; 15(17): 4235.     CrossRef
  • Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers
    Jeeyeon Lee, Ji Yeon Ham, Ho Yong Park, Jin Hyang Jung, Wan Wook Kim, Byeongju Kang, Yee Soo Chae, Soo Jung Lee, In Hee Lee, Nan Young Lee
    Scientific Reports.2022;[Epub]     CrossRef
  • Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer
    Jeong Dong Lee, Won-Ji Ryu, Hyun Ju Han, Tae Yeong Kim, Min Hwan Kim, Joohyuk Sohn
    Cancers.2022; 14(10): 2405.     CrossRef
  • Discovery of BRCA1/BRCA2 founder variants by haplotype analysis
    Won Kyung Kwon, Hyeok-Jae Jang, Jeong Eon Lee, Yeon Hee Park, Jai Min Ryu, Jonghan Yu, Ja-Hyun Jang, Jong-Won Kim
    Cancer Genetics.2022; 266-267: 19.     CrossRef
  • Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea
    Joohyun Hong, Jiyun Lee, Minsuk Kwon, Ji-Yeon Kim, Jong-Won Kim, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
    Diagnostics.2021; 11(2): 370.     CrossRef
  • Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study
    Joo Heung Kim, Sunggyun Park, Hyung Seok Park, Ji Soo Park, Seung-Tae Lee, Sung-Won Kim, Jong Won Lee, Min Hyuk Lee, Sue K. Park, Woo-Chul Noh, Doo Ho Choi, Wonshik Han, Sung Hoo Jung
    Scientific Reports.2021;[Epub]     CrossRef
  • A Population-Based Analysis of BRCA1/2 Genes and Associated Breast and Ovarian Cancer Risk in Korean Patients: A Multicenter Cohort Study
    Kyung-Sun Park, Woochang Lee, Moon-Woo Seong, Sun-Young Kong, Kyung-A Lee, Jung-Sook Ha, Eun-Hae Cho, Sung-Hee Han, Inho Park, Jong-Won Kim
    Cancers.2021; 13(9): 2192.     CrossRef
  • 9,315 View
  • 189 Download
  • 7 Web of Science
  • 7 Crossref
Close layer
The Effect of Simulation on Recurrence after Breast-Conserving Surgery and Radiotherapy: Preliminary Results
Ji-Yoon Kim, Yeon-Sil Kim, Mi-Ryung Ryu, Sung-Whan Kim, Chul-Seung Kay, Sei-Chul Yoon, Woo-Chan Park, Byung-Joo Song, Se-Jeong Oh, Sang-Seol Jung, Jong-Man Won, Seung-Nam Kim, Su-Mi Chung
Cancer Res Treat. 2006;38(1):40-47.   Published online February 28, 2006
DOI: https://doi.org/10.4143/crt.2006.38.1.40
AbstractAbstract PDFPubReaderePub
Purpose

To evaluate the effect of the simulation method on recurrence among the patients who received radiotherapy after breast-conserving surgery (BCS) for early breast carcinoma.

Materials and Methods

Between 1995 and 2000, 70 patients with stage I-II breast carcinoma underwent breast-conserving surgery and adjuvant radiotherapy. Twenty nine patients (41.4%) were simulated with the 2D contour-based method (September 1995 to August 1997) and 41 patients (58.6%) were simulated with the 3D CT-based method (September 1997 to February 2000). To analyze the effect of the simulation method, the patient and treatment characteristics were compared.

Results

The characteristics were similar for the patients between the 2D contour-based simulation group and the 3D CT-based simulation group. During a median follow-up period of 75 months, 4 (13.8%) of 29 patients who were treated with 2D simulation and 1 (2.4%) of 41 patients who were treated with 3D simulation group developed treatment failure. The five-year survival rates were 89.2% and 95.1% between the 2D and 3D simulation groups (p=0.196). The five-year disease free survival (DFS) rates were 86.2% and 97.5% between the 2D and 3D simulation groups (p=0.0636). On univariate analysis, age > 40 (p= 0.0226) and the number of dissected axillary lymph node ≥ 10 (p=0.0435) were independent predictors of improved 5-year DFS.

Conclusions

Although our data showed marginal significance for the DFS between the two groups, it is insufficient, due to the small number of patients in our study, to prove whether 3D CT-based simulation might improve the DFS and reduce the risk of recurrence when compared with 2D contour-based simulation. Further study is needed with a larger group of patients.

  • 11,469 View
  • 46 Download
Close layer
Clinical Experience of Patients with Ductal Carcinoma In Situ of the Breast Treated with Breast-Conserving Surgery plus Radiotherapy: A Preliminary Report
Ji-Young Jang, Mi-Ryeong Ryu, Sung-Whan Kim, Chul-Seung Kay, Yeon-Sil Kim, Yoon-Kyeong Oh, Hyung-Chul Kwon, Sei-Chul Yoon, Woo-Chan Park, Byung-Joo Song, Se-Jeong Oh, Sang-Seol Jung, Jong-Man Won, Seung-Nam Kim, Su-Mi Chung
Cancer Res Treat. 2005;37(6):344-348.   Published online December 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.6.344
AbstractAbstract PDFPubReaderePub
Purpose

Breast-conserving therapy (BCT) is a practical alternative to mastectomy for treating ductal carcinoma in situ (DCIS). We reviewed our experience for treating patients with DCIS of the breast to evaluate the outcome after performing breast-conserving surgery plus radiotherapy (BCS-RT).

Materials and Methods

Between January 1983 and December 2002, 25 patients with clinically or mammographically detected DCIS were treated by BCS-RT. One patient was diagnosed with bilateral DCIS. Thirteen cases (50%) had symptomatic lesions at presentation. All 26 cases of 25 patients underwent BCS such as lumpectomy, partial mastectomy or quadrantectomy. All of them received whole breast irradiation to a median dose of 50.4 Gy. Twenty-four cases (92.3%) received a boost to the tumor bed for a median total dose of 59.4 Gy. The median follow up period was 67 months (range: 38 to 149 months).

Results

Two cases (7.7%) experienced ipsilateral breast tumor recurrence (IBTR) after BCS-RT. The histology results at the time of IBTR showed invasive ductal carcinoma (IDC), and the median time to IBTR was 25.5 months. On the univariate analysis, there were no significant factors associated with IBTR in the DCIS patients. The three-year local recurrence free survival rate was 96.0% and the overall survival rate was 96.3%.

Conclusion

After the treatment for DCIS, the IBTR rate in our study was similar to other previous studies. Considering that we included patients who had many symptomatic lesions, close or positive margins and less that complete early data, our result is comparable to the previous studies. We could not find the prognostic significant factors associated with IBTR after BCS-RT. A longer follow up period with more patients would be required to evaluate the role of any predictive factors and to confirm these short-term results.

  • 8,526 View
  • 56 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP